论文部分内容阅读
采用酶联免疫吸附法(ELISA)技术,对25例IDDM患者治疗前后及40例NIDDM患者血清可溶性sIL-2R水平进行测定。结果发现:IDDM患者血清sIL-2R明显高于正常对照组,经治疗后血清sIL-2R水平下降;而NIDDM患者血清sIL-2R无明显变化。因此血清sIL-2R水平变化及动态观察可作为机体免疫系统激活状态的指标之一,及IDDM患者诊断,治疗和预后的监测指标。
Serum soluble sIL-2R levels were measured in 25 patients with IDDM before and after treatment and 40 with NIDDM by enzyme-linked immunosorbent assay (ELISA). The results showed that the serum sIL-2R in IDDM patients was significantly higher than that in the normal control group, the level of serum sIL-2R decreased after treatment, while the serum sIL-2R in NIDDM patients did not change significantly. So serum sIL-2R level changes and dynamic observation can be used as one of the indicators of the immune system activation status, and IDDM patients diagnosis, treatment and prognosis monitoring indicators.